Clinical Trials Logo

Central Nervous System Neoplasms clinical trials

View clinical trials related to Central Nervous System Neoplasms.

Filter by:

NCT ID: NCT00005976 Completed - Clinical trials for Brain and Central Nervous System Tumors

Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma

Start date: May 2000
Phase: Phase 2
Study type: Interventional

Phase I/II trial to study the effectiveness of pyrazoloacridine plus carboplatin in treating patients who have recurrent glioma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

NCT ID: NCT00005955 Completed - Neuroblastoma Clinical Trials

Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors

Start date: August 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Chemotherapy combined with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of temozolomide followed by radiation therapy in treating children who have newly diagnosed malignant central nervous system tumors.

NCT ID: NCT00005954 Completed - Clinical trials for Brain and Central Nervous System Tumors

Temozolomide in Treating Patients With Brain Metastases

Start date: August 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have brain metastases.

NCT ID: NCT00005952 Completed - Ovarian Cancer Clinical Trials

Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors

Start date: August 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of temozolomide when given with peripheral stem cell transplantation and to see how well they work in treating children with newly diagnosed malignant glioma or recurrent CNS tumors or other solid tumors.

NCT ID: NCT00005951 Completed - Clinical trials for Brain and Central Nervous System Tumors

Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma

Start date: August 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent primary malignant glioma.

NCT ID: NCT00005859 Completed - Clinical trials for Brain and Central Nervous System Tumors

Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma

Start date: May 16, 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent or progressive malignant glioma.

NCT ID: NCT00005855 Completed - Clinical trials for Brain and Central Nervous System Tumors

Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma

Start date: July 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of efaproxiral when given with carmustine and to see how well they work in treating patients with progressive or recurrent malignant glioma.

NCT ID: NCT00005826 Completed - Clinical trials for Brain and Central Nervous System Tumors

Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme

Start date: March 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have glioblastoma multiforme.

NCT ID: NCT00005813 Completed - Clinical trials for Brain and Central Nervous System Tumors

Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme

Start date: March 1997
Phase: Phase 1
Study type: Interventional

RATIONALE: Bispecific antibodies plus white blood cells may be able to locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of combining bispecific antibodies with white blood cells in treating patients who have recurrent or refractory glioblastoma multiforme.

NCT ID: NCT00005796 Completed - Clinical trials for Brain and Central Nervous System Tumors

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

Start date: February 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Inserting a specific gene into a person's peripheral stem cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus gene therapy in treating patients who have CNS tumors.